[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nonmelanoma-skin-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nonmelanoma-skin-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100611515","vitamin-d-effects-on-immune-microenvironment-of-nonmelanoma-skin-cancer-after-photodynamic-therapy-pdt-100611515",false,"NCT07241585","Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","Inclusion Criteria:\n\n* Must be an adult participant (\\> 18 yrs) who is scheduled to undergo Mohs surgery or ED\\&C within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic.\n* Must have at least one BCC or SCC tumor eligible for removal by Mohs surgery.\n* The original tumor size prior to biopsy must be \\>1.0 cm (in the longest diameter).\n* Participants of any ethnic group are eligible for this trial.\n* Must provide informed consent to participate in the trial.\n* Participant must live in Ohio (Groups 2 \\& 3), because Research Pharmacy cannot ship the study drugs outside of the state.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Currently being treated for other cancers with medical or radiation therapy\n* Known hypersensitivity to 5-aminolevulinic acid\n* History of a photosensitivity disease, e.g., porphyria cutanea tarda","ALL","18 Years",{"count":18,"type":19},54,"ESTIMATED","INTERVENTIONAL",[22],"NA","This research study is for people who have been diagnosed with a nonmelanoma skin cancer (either basal cell carcinoma or squamous cell carcinoma) and are planning to receive either Mohs surgery or ED\\&C (electrodessication \\& curettage) as part of clinical care. The purpose of this study is to understand how photodynamic therapy (PDT) with or without Vitamin D can promote an immune response to skin cancer.\n\nFor this study, participants will be randomized (randomly assigned) and asked to take Vitamin D or placebo for 6 days and come to the clinic for a single PDT treatment 1-14 days prior to their surgery. At this visit, photographs of participant's skin cancer will be taken, and participants will undergo PDT treatment. The study team will also take photos on the day of Mohs surgery or ED\\&C. There will be up to two blood draws for research.\n\nIf participants do not want to come in for a PDT treatment prior to their Mohs surgery or ED\\&C, they will have the option to participate by only allowing the study team to collect data about their skin cancer and their tissue from Mohs surgery or ED\\&C.",[25,26,27],"Nonmelanoma Skin Cancer","Basal Cell Carcinoma","Squamous Cell Carcinoma",[29,30,31,32,33,34],"Mohs surgery","Electrodessication & curettage","ED&C","Photodynamic therapy","PDT","Vitamin D","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2026-02-25",{"date":43,"type":19},"2027-08",{"name":45,"class":46},"Case Comprehensive Cancer Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100642565","therapeutic-induction-of-dermal-remodeling-in-veterans-to-prevent-actinic-neoplasia-caused-by-chronic-environmental-exposure-to-ultraviolet-radiation-100642565","NCT07648407","Therapeutic Induction of Dermal Remodeling in Veterans to Prevent Actinic Neoplasia Caused by Chronic Environmental Exposure to Ultraviolet Radiation","Inclusion Criteria:\n\n* Adult Males and Females age 60 and older with 5 or more AKs on each forearm\n* Skin type fair-Fitzpatrick I-II\n* Able to comprehend procedures and risks\n\nExclusion Criteria:\n\n* More than 10 AKs on an extremity, or AKs that are large (2-3+)\n* Medical history of Diabetes\n* Coagulopathy or easy bleeding\n* History of poor wound healing or scarring\n* Large tattoos that can interfere with study\n* Other serious health issues and other skin diseases that could interfere with the study\n* Recent (within 1 year) field therapies such as Efudex cream or PDT to forearms\n* Planning to leave region in next 4 years","60 Years",{"count":56,"type":19},96,[22],"The investigators' previous studies demonstrate geriatric subject skin responds differently to ultraviolet B (UVB) light compared to young subject skin, which contribute to increased rates of nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) development in geriatric populations. Previously, the investigators have shown that therapeutic dermal remodeling interventions (e.g., fractionated laser resurfacing and microneedling) can restore appropriate skin responses to UVB in geriatric skin. The investigators also demonstrated fractionated laser resurfacing (FLR) reduced rates of NMSC and AK development (compared to untreated control skin) in at risk geriatric subjects.\n\nThis interventional study will assess the ability of two therapeutic dermal remodeling therapies, microneedling and trichloroacetic acid chemical (TCA) peel, to impact NMSC and AK development in at risk geriatric subjects. Geriatric subjects will be enrolled into one of two study groups. In the first group, one arm will be treated with microneedling and the other arm will not be treated on day 1. In the second group, one arm will be treated with TCA peel and the other arm will not be treated on day 1. Subjects will subsequently be monitored for number of NMSC and AK on treated and untreated (control) forearms in each group. In addition to monitoring NMSC and AK development, subjects at the Richard L. Roudebush VAMC will undergo skin punch biopsy at one of their follow up visits for microscopic and molecular analyses of treated and untreated skin.",[25,60],"Actinic Keratosis",[62,63,64,65,66],"Nonmelanoma skin cancer","Actinic keratosis","Ultraviolet light","Microneedling","Chemical peel","NOT_YET_RECRUITING","2026-06-09",{"date":70,"type":39},"2026-06-15",{"date":72,"type":19},"2026-10-01",{"date":74,"type":19},"2030-09-30",{"name":76,"class":77},"VA Office of Research and Development","FED",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":20,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":47},"100447565","sentinel-lymph-node-biopsy-for-cutaneous-squamous-cell-carcinoma-of-the-head-and-neck-100447565","NCT05108090","Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck","Inclusion Criteria:\n\n* Patients ≥ 18 years old at the time of informed consent\n* Ability to provide written informed consent and HIPAA authorization\n* Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging\n* Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)\n* Able to undergo general anesthesia for sentinel lymph node biopsy\n* Able to undergo CT scan with contrast or MRI with contrast\n* Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging\n\nExclusion Criteria:\n\n* Clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases\n* Known biopsy proven synchronous primary cutaneous squamous cell carcinoma\n* Pregnant patients\n* Patients unable to undergo general anesthesia\n* Patient unable to receive contrasted imaging studies\n* Patient unable to receive and\u002For allergic to 99m-Technetium sulfur colloid",{"count":86,"type":19},94,[22],"The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.",[27,25,90],"Cutaneous Squamous Cell Carcinoma",[92],"sentinel lymph node biopsy","2025-06-06",{"date":95,"type":39},"2025-06-11",{"date":97,"type":39},"2021-10-25",{"date":99,"type":19},"2026-09",{"name":101,"class":46},"Indiana University"]